Search - tctmd.com

Displaying 1 - 20 of 54

Sort: Relevancy | Date

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

Real-world Data Reiterate Value of CT-First Strategy to Rule Out Obstructive CAD

News Conference News

Real-world Data Reiterate Value of CT-First Strategy to Rule Out Obstructive CAD

February 02, 2024

With New LDL Goalposts in FH, Combo Therapy Must Start Early

News Conference News EAS 2023

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Michael O'Riordan

May 29, 2023

Multipronged Outreach to Families Can Boost FH Cascade Screening: IMPACT-FH

News Conference News EAS 2023

Multipronged Outreach to Families Can Boost FH Cascade Screening: IMPACT-FH

Michael O'Riordan

May 26, 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

News Conference News EuroPCR 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Michael O'Riordan

May 18, 2023

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

News Conference News TCT 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

September 22, 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

August 28, 2022

Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively

News Conference News EAS 2022

Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively

Michael O'Riordan

May 27, 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

News Conference News EAS 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Michael O'Riordan

May 26, 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

News Conference News EAS 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

Michael O'Riordan

May 24, 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

News Conference News ACC 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

April 03, 2022

ApoB Gains Ground as Best Lipid Predictor of MI Risk

News Conference News AHA 2021

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Michael O'Riordan

November 22, 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

News Conference News ESC 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

Michael O'Riordan

September 03, 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

News Conference News ESC 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

Michael O'Riordan

September 02, 2021

Both Acute and Chronic Myocardial Injury in COVID-19 Impede 6-Month Survival

News Conference News ESC 2021

Both Acute and Chronic Myocardial Injury in COVID-19 Impede 6-Month Survival

September 01, 2021

High Ischemic Risk and Bleeding Risk: A Delicate Balance Post-PCI

News Conference News EAS 2021

High Ischemic Risk and Bleeding Risk: A Delicate Balance Post-PCI

Michael O'Riordan

June 08, 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

News Conference News EAS 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Michael O'Riordan

June 03, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.